Thomas J. Cradick

Atara Biotherapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index8.8kcitations43works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(36), Advanced biosensing and bioanalysis techniques(14), RNA Interference and Gene Delivery(13), RNA and protein synthesis mechanisms(9), HIV Research and Treatment(4)

Publications43 total

Serum factors create species-specific barriers to hepatic gene transfer by lipid nanoparticles in liver-humanized mice
Molecular Therapy — Methods & Clinical Development·2025· 5 citedOpen Access
Correction: Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates
Gene Therapy·2024· 1 citedOpen Access
Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates
Gene Therapy·2023· 32 citedOpen Access
Strategic self-limiting production of infectious HIV particles by CRISPR in permissive cells
Molecular Therapy — Nucleic Acids·2023· 11 citedOpen Access
In vivo genome editing at the albumin locus to treat methylmalonic acidemia
Molecular Therapy — Methods & Clinical Development·2021· 19 citedOpen Access
Base Editors Flex Sights on Sickle-Cell Disease
The CRISPR Journal·2021
Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods
The CRISPR Journal·2020· 48 citedOpen Access
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Blood·2018· 184 citedOpen Access
Crispr/Cas9- Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies
Blood·2016· 3 cited
Induction of Fetal Hemoglobin Synthesis By Crispr/Cas9-Mediated Disruption of the β-Globin Locus Architecture
Blood·2016· 1 cited
Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia
Blood·2016· 4 cited
A Burden of Rare Variants Associated with Extremes of Gene Expression in Human Peripheral Blood
The American Journal of Human Genetics·2016· 92 citedOpen Access
The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells
Molecular Therapy·2016· 249 citedOpen Access
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing
Molecular Therapy·2016· 128 citedOpen Access
Cellular Therapies: Gene Editing and Next-Gen CAR T Cells
2016· 1 cited
Strategies to Determine Off-Target Effects of Engineered Nucleases
Advances in experimental medicine and biology·2016· 2 cited
TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCs
Molecular Therapy — Nucleic Acids·2016· 41 citedOpen Access
Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome
Molecular Therapy·2015· 253 citedOpen Access
Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies
Blood·2015· 5 cited
Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering
PLoS ONE·2015· 51 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Gang Bao(18), Eli J. Fine(13), Ciaran M. Lee(10), Gang Bao(8), Matthew H. Porteus(6), Ante S. Lundberg(5), Toni Cathomen(4), Fulvio Mavilio(4), Annarita Miccio(4), Yanni Lin(4), Jennifer Gordon(4), Christopher J. Antico(3), Claudio Mussolino(3), Annalisa Lattanzi(3), Anton P. McCaffrey(3), Tricia H. Burdo(3), Chen Chen(3), Rafal Kaminski(3), Shuren Liao(3), Kamel Khalili(3)